Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability

Diabetic Medicine

Volumn 15, Issue 10, 1998, Pages 870-877

  O'Neal, D N ^a   O'Brien, R C ^b   Timmins, K L ^b   Grieve, G D ^a   Lau, K P ^a   Nicholson, G C ^a   Kotowicz, M A ^a   Best, J D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Dyslipidaemia; Lipid modifying therapy; Low density lipoprotein; Type 2 diabetes mellitus

Indexed keywords

BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; GEMFIBROZIL; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; GEL ELECTROPHORESIS; GLUCOSE BLOOD LEVEL; HUMAN; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; BLOOD COAGULATION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OXIDATION-REDUCTION;

EID: 0031691405     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199810)15:10<870::AID-DIA680>3.0.CO;2-8     Document Type: Article

References (61)

1. Betteridge DJ. Diabetic dyslipidemia. Am J Med. 1994; 96 (suppl 6A): 25S-31S.
2. Tomkin GH, Owens D. Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabetes Metab Rev 1994; 10: 225-252.
3. Howard BV, Howard WJ. Dyslipidemia in non-insulin-dependent diabetes mellitus. Endocrine Rev 1994; 15: 263-274.
4. Laakso M. Epidemiology of diabetic dyslipidemia. Diabetes Rev 1995; 3: 408-422.
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids and the role of obesity in coronary heart disease for women. The Framingham Study. Ann Intern Med 1977; 87: 393-397.
6. Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Basett ML, Bierman EL. Abnormal concentration of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 1982; 31: 126-131.
7. Barrett-Connor E, Grundy SM, Holbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 1982; 115: 657-663.
8. Uusitupa M, Siitonen O, Voutilainen E, Aro A, Hersioo K, Pyorala K. Risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
9. West KM, Ahuja MMS, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors': as determinants of arterial disease in nine diabetic population samples from the WHO multinational Study. Diabetes Care 1983; 6: 361-369.
10. Santon RJ, Willis PW, Fajans SS. Atherosclerosis in diabetes mellitus. Correlations with serum lipid levels, adiposity and serum insulin level. Arch Intern Med 1972; 130: 833-843.
11. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
12. Reckless JPD, Betteridge DJ, Wu P, Payne B, Galton DJ. High density and low density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med J 1978; 1: 883-886.
13. 2 cholesterol with coronary heart disease in non-insulin-dependent diabetes. Diabetes 1979; 28: 836-840.
14. Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984; 27: 568-537.
15. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein sub-class patterns and risk of myocardial infarction. J Am Med Assoc 1988; 260: 1917-1921.
16. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arteriosclerosis 1992; 12: 187-195.
17. Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, Marks R. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinaemia and atherosclerosis. Diabetes 1990; 39: 1527-1533.
18. Feingold KR, Grunfeld C, Coerrier W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb 12: 1496-1502.
19. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 1994; 17: 1164-1171.
20. O'Brien SF, Watts GF, Playford DA, Burke V, O'Neal DN, Best JD. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabetic Med 1997; 14: 974-978.
21. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. Arteriosclerosis and Thrombosis 1991; 11: 298-306.
22. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 347-349.
23. Steinbrecher U. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-3608.
24. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoproteins. Arteriosclerosis 1983; 3: 149-159.
25. Morel DW, Hessler JR, Chisolm CM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-1076.
26. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia. Diabetes 1989; 38: 364-372.
27. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990; 66: 16B-21B.
28. Galletti F, Gasparro MG, Sensi S. A multicenter gemfibrozil study in type II diabetic patients with hyperlipidemia. In: Descovich GC, et al., eds. Atherosclerosis and Cardiovascular Disease, vol 4. Bologna: Edritice Composition, 1989.
29. Shen D-C, Fuh MMT, Shieh S-M, Chen Y-D, Reaven GM. Effect of gemfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991; 73: 503-510.
30. Steiner G. Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Diabetes Care 1991; 14: 1077-1081.
31. Vinik Al, Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 1993; 16: 37-44.
32. Kahri J, Vuorine-Markkola H, Tilly-Kiesi M, Lahdenpera S, Taskinen M-R. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesterol ester transfer protein activity. Atherosclerosis 1993; 102: 79-89.
33. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen M-R. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993; 16: 584-592.
34. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky Jr GJ, Porte Jr D. Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-568.
35. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in NIDDM. J Am Med Assoc 1990; 264: 723-726.
36. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem 1972; 18: 499-502.
38. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, et al. Single vertical spin density gradient ultracentrifugation. Segrest JP, Albers JJ, eds. Methods in Enzymology. 1986; 128: 341-344.
39. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
40. O'Neal DN, Lee P, Murphy B, Best JD. Low density lipoprotein particle size distribution in end stage renal disease treated with haemodialysis or peritoneal dialysis. Am J Kid Dis 1996; 27: 83-92.
41. Esterbaur H, Streigl C, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of LDL. Free Rad Res Com 1989; 6: 67-75.
42. Saleen A, Krief A, Fretz K. Improved micromethod of plasma fibronogen unaffected by heparin therapy. Am J Clin Path 1975; 63: 426-433.
43. Giddings JC. The investigation of hereditary coagulation disorders. In: Thompson J, ed. Blood Coagulation and Haemostasis - a Practical Guide, 2nd edn. London: Churchill Livingstone, 1980: 78-79.
44. Declerck PJ. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids, with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 69: 381-387.
45. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley, 1986: 186-241.
46. Mannien V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment. Circulation 1992; 85: 37-45.
47. Miller CW, Mtambi JM. Peroxisome proliferators induce liver stearoyl-CoA desturase 1 gene expression. Proc Natl Acad Sci USA 1996; 93: 9443-9448.
48. Nikkila EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridemia. Proc R Soc Med 1984; 69 (suppl 2): 58-63.
49. Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and triglycerides in man. J Am Med Assoc 1984; 251: 2241-2246.
50. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-1274.
51. Coresh J, Kwiterovitch PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34: 1687-1697.
52. Steiner G. Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077-1081.
53. Shen DC, Fuh MM, Shieh SM, Chen YD, Reaven GM. Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus. J Clin End Metab 1991; 73: 503-510.
54. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990; 66: 16B-21B.
55. Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen M-R. Lowering of triglycerides by gemfibrozil affects neither the gluco-regulatory nor antilipolytic action of insulin in non-insulin-dependent diabetic patients. Diabetologia 1993; 36: 161-169.
56. Bredie SJ, de Bruin PN, Kastelein JJ, Stelenhoef AF. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins; low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995; 75: 348-353.
57. Schwartzkopff W, Menzel B, Stern, K. Gemfibrozil in patients with primary hyperlipoproteinemias. Therapiewoche 1985; 35: 1388-1389.
58. Zambrana JL, Velasco F, Castro P, Concha M, Valles F, Montilla P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol 1997; 80: 836-840.
59. Juhan-Vague I, Vague Ph, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes & Metabolism 1987; 13: 331-336.
60. Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-208.
61. Koskinen P, Mantarri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki heart study. Diabetes Care 1992; 15: 820-825.